Panbela therapeutics to receive a total up to $9.5 million for divestiture of assets within eflornithine (dfmo) pediatric neuroblastoma program to us worldmeds

Minneapolis and louisville, ky., july 19, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has divested certain assets in its eflornithine pediatric neuroblastoma program to us worldmeds ® 1 (uswm), a kentucky-based specialty pharmaceutical company.
PBLA Ratings Summary
PBLA Quant Ranking